DLG5 R30Q does not predict response to infliximab therapy in Hungarian patients with Crohn's disease
S Fischer, K Claes, L Lakatos, I Altorjay, T Molnár, K Palatka, A Kovacs, M Papp, J Osztovits, P Rutgeerts, S Vermeire, J Papp · Zeitschrift für Gastroenterologie · 2006 · Heft 06
Bibliografische Angaben
Zusammenfassung
Aim: Recent data from Germany have suggested that specific haplotypic variants of the DLG5 gene on chromosome 10q23 are associated with susceptibility to inflammatory bowel disease (IBD). Since DLG5 has been implicated in maintaining intracellular signal transduction and cell-cell contact, it might be hypothesized that DLG5 affects inflammatory responses and, as a consequence, also response to anti-inflammatory therapy. In this study, we investigated the DLG R30Q variant allele and response to infliximab therapy in CD patients. Methods: 60 unrelated CD patients (m/f: 25/35, age: 34.3±11.1 years, duration: 7.9±5.…
